| |
| |
| Exchange: |
New York Stock Exchange |
| Security
Type: |
Common |
| Shares
Out: |
956,580,000 |
| Market
Cap: |
825.39(B) |
| Last
Volume: |
5,013,694 |
Avg
Vol: |
3,371,534 |
| 52
Week Range: |
$625.65 - $929.72 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Drug Manufacturers - Major |
|
Member Indexes:
|
| |
S&P COMPOSITE 1500 |
|
NYSE COMPOSITE |
| |
S&P 500 |
|
Rankings:
|
|
| Insider 3 Months : 19.5 |
| Insider 6 Months : 19.5 |
| Insider 3/6 Months : 38.1 |
|
| Guru Rank Number : 412 |
| Guru Rank Value : 5.2 |
| Guru Occurances : 3 |
|
|
|
|
|
| |
|
Company Profile Eli Lilly and Company discovers, develops, manufactures, and markets products in a single business segment: human pharmaceutical products. Co.'s products include: diabetes products, oncology products, immunology products, neuroscience products, and other therapies. Co.'s diabetes products include: Baqsimi®, Basaglar®, Humalog®, Humulin®, Jardiance®, Lyumjev®, Trajenta®, and Trulicity®. Co.'s oncology products include: Alimta®, Cyramza®, Erbitux®, Retevmo®, Tyvyt®, and Verzenio®. Co.'s immunology products include: Olumiant® and Taltz®. Co.'s neuroscience products include: Cymbalta®, Emgality®, Reyvow®, and Zyprexa®. Co.'s other therapies include: Bamlanivimab, Cialis®, and Forteo®.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
6,987 |
6,987 |
6,987 |
6,987 |
| Total Buy Value |
$4,537,301 |
$4,537,301 |
$4,537,301 |
$4,537,301 |
| Total People Bought |
8 |
8 |
8 |
8 |
| Total Buy Transactions |
8 |
8 |
8 |
8 |
| Total Shares Sold |
1,205,908 |
1,488,158 |
2,370,058 |
5,239,637 |
| Total Sell Value |
$984,474,504 |
$1,211,546,723 |
$2,147,483,647 |
$2,147,483,647 |
| Total People Sold |
3 |
3 |
4 |
5 |
| Total Sell Transactions |
14 |
17 |
28 |
70 |
| End Date |
2025-08-03 |
2025-05-02 |
2024-11-01 |
2023-11-02 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Alvarez Ralph |
Director |
– • – |
2025-10-20 |
4 |
A |
$808.96 |
$11,750 |
D/D |
15 |
55,152 |
|
- |
|
| Greene Gabrielle E |
Director |
– • – |
2025-10-20 |
4 |
A |
$808.96 |
$4,958 |
D/D |
6 |
2,728 |
|
- |
|
| Hedley Mary Lynne |
Director |
– • – |
2025-10-20 |
4 |
A |
$808.96 |
$9,917 |
D/D |
12 |
2,016 |
|
- |
|
| Luciano Juan R |
Director |
– • – |
2025-10-20 |
4 |
A |
$808.96 |
$14,833 |
D/D |
18 |
16,474 |
|
- |
|
| Fyrwald J Erik |
Director |
– • – |
2025-10-20 |
4 |
A |
$808.96 |
$9,917 |
D/D |
12 |
74,764 |
|
- |
|
| Lilly Endowment Inc |
|
– – • |
2025-10-10 |
4 |
S |
$862.34 |
$3,157,722 |
D/D |
(3,658) |
94,533,320 |
|
-1% |
|
| Lilly Endowment Inc |
|
– – • |
2025-10-09 |
4 |
S |
$848.63 |
$9,038,055 |
D/D |
(10,602) |
94,536,978 |
|
1% |
|
| Lilly Endowment Inc |
|
– – • |
2025-10-08 |
4 |
S |
$848.46 |
$86,234,874 |
D/D |
(101,420) |
94,547,580 |
|
0% |
|
| Lilly Endowment Inc |
|
– – • |
2025-10-07 |
4 |
S |
$848.01 |
$22,722,401 |
D/D |
(26,795) |
94,649,000 |
|
-0% |
|
| Lilly Endowment Inc |
|
– – • |
2025-10-06 |
4 |
S |
$848.30 |
$137,041,657 |
D/D |
(161,183) |
94,675,795 |
|
0% |
|
| Lilly Endowment Inc |
|
– – • |
2025-10-03 |
4 |
S |
$821.42 |
$161,220,401 |
D/D |
(192,404) |
94,836,978 |
|
-1% |
|
| Lilly Endowment Inc |
|
– – • |
2025-10-02 |
4 |
S |
$821.09 |
$92,503,361 |
D/D |
(112,596) |
95,029,382 |
|
-3% |
|
| Lilly Endowment Inc |
|
– – • |
2025-10-01 |
4 |
S |
$765.75 |
$107,363,016 |
D/D |
(135,193) |
95,357,800 |
|
-2% |
|
| Lilly Endowment Inc |
|
– – • |
2025-10-01 |
4 |
S |
$808.33 |
$177,290,448 |
D/D |
(215,822) |
95,141,978 |
|
-2% |
|
| Lilly Endowment Inc |
|
– – • |
2025-09-30 |
4 |
S |
$763.10 |
$86,793,274 |
D/D |
(113,694) |
95,492,993 |
|
-11% |
|
| Lilly Endowment Inc |
|
– – • |
2025-09-19 |
4 |
S |
$763.05 |
$18,058,643 |
D/D |
(23,665) |
95,606,687 |
|
-12% |
|
| Lilly Endowment Inc |
|
– – • |
2025-09-18 |
4 |
S |
$763.29 |
$81,531,959 |
D/D |
(106,626) |
95,630,352 |
|
-11% |
|
| Alvarez Ralph |
Director |
– • – |
2025-09-15 |
4 |
A |
$748.19 |
$11,750 |
D/D |
16 |
55,138 |
|
- |
|
| Fyrwald J Erik |
Director |
– • – |
2025-09-15 |
4 |
A |
$748.19 |
$9,917 |
D/D |
13 |
74,751 |
|
- |
|
| Luciano Juan R |
Director |
– • – |
2025-09-15 |
4 |
A |
$748.19 |
$14,834 |
D/D |
20 |
16,456 |
|
- |
|
| Greene Gabrielle E |
Director |
– • – |
2025-09-15 |
4 |
A |
$748.19 |
$4,958 |
D/D |
7 |
2,722 |
|
- |
|
| Hedley Mary Lynne |
Director |
– • – |
2025-09-15 |
4 |
A |
$748.19 |
$9,917 |
D/D |
13 |
2,003 |
|
- |
|
| Hernandez Edgardo |
EVP & Pres., Mfg. Operations |
• – – |
2025-09-05 |
4 |
GD |
$0.00 |
$0 |
D/D |
17 |
39,731 |
|
- |
|
| Zakrowski Donald A |
SVP, Finance, & CAO |
• – – |
2025-08-28 |
4 |
AS |
$734.93 |
$734,930 |
D/D |
(1,000) |
3,840 |
|
18% |
|
| Fyrwald J Erik |
Director |
– • – |
2025-08-18 |
4 |
A |
$698.05 |
$9,916 |
D/D |
14 |
74,592 |
|
- |
|
1454 Records found
|
|
Page 1 of 59 |
|
|
18.36 (2.17%) 
